Published in Int J Oncol on April 01, 2004
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med (2006) 0.93
Glycosylation and liver cancer. Adv Cancer Res (2015) 0.88
Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery. J Proteome Res (2009) 0.85
Contribution of laser microdissection-based technology to proteomic analysis in hepatocellular carcinoma developing on cirrhosis. Proteomics Clin Appl (2007) 0.79
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Novel technologies for the discovery and quantitation of biomarkers of toxicity. Toxicology (2007) 0.78
Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. Br J Cancer (2006) 0.78
Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One (2014) 0.75
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology (2014) 1.93
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med (2002) 1.75
CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol (2005) 1.67
Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med (2006) 1.61
Small supernumerary marker chromosomes (SMCs): genotype-phenotype correlation and classification. Hum Genet (2003) 1.57
Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am J Hum Genet (2010) 1.49
Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J Invest Dermatol (2006) 1.48
Calciphylaxis: no therapeutic concepts for a poorly understood syndrome? J Dtsch Dermatol Ges (2006) 1.43
Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges (2005) 1.40
Regulation of the anaphase-promoting complex by the COP9 signalosome. Cell Cycle (2009) 1.40
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging (2010) 1.39
PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res (2003) 1.33
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol (2002) 1.32
Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res (2004) 1.30
Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia (2006) 1.24
Spatial segmentation of imaging mass spectrometry data with edge-preserving image denoising and clustering. J Proteome Res (2010) 1.20
Mechanical stretch stimulates protein kinase B/Akt phosphorylation in epidermal cells via angiotensin II type 1 receptor and epidermal growth factor receptor. J Biol Chem (2004) 1.19
Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol (2011) 1.17
Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol (2012) 1.15
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem (2007) 1.12
Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol (2004) 1.11
Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol (2005) 1.10
Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2011) 1.10
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr (2003) 1.08
Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int J Oncol (2006) 1.06
A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res (2004) 1.05
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen (2011) 1.04
Is there a higher incidence of maternal uniparental disomy 14 [upd(14)mat]? Detection of 10 new patients by methylation-specific PCR. Am J Med Genet A (2006) 1.04
Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology (2005) 1.03
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest (2002) 1.02
Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res (2007) 1.01
Inference of dynamical gene-regulatory networks based on time-resolved multi-stimuli multi-experiment data applying NetGenerator V2.0. BMC Syst Biol (2013) 1.01
Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer (2005) 1.01
Down-regulation of MTUS1 in human colon tumors. Oncol Rep (2010) 1.01
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost (2006) 1.00
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol (2003) 0.98
Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol (2010) 0.98
Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitro (2008) 0.98
Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci (2003) 0.97
The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. FASEB J (2007) 0.96
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res (2008) 0.95
Fluid shear stress-induced transcriptional activation of the vascular endothelial growth factor receptor-2 gene requires Sp1-dependent DNA binding. FEBS Lett (2003) 0.95
Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges (2012) 0.95
A further case with a small supernumerary marker chromosome (sSMC) derived from chromosome 1--evidence for high variability in mosaicism in different tissues of sSMC carriers. Prenat Diagn (2007) 0.95
Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light. J Invest Dermatol (2007) 0.94
Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94
Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia (2006) 0.93
Reproducible identification of the causative drug of a fixed drug eruption by oral provocation and lesional patch testing. Contact Dermatitis (2002) 0.93
Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. Int J Cancer (2009) 0.93
Derivative chromosome 1 and GLUT1 deficiency syndrome in a sibling pair. Mol Cytogenet (2010) 0.92
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. Oncol Res (2004) 0.92
Prader-Willi syndrome with a karyotype 47,XY,+min(15)(pter->q11.1:) and maternal UPD 15--case report plus review of similar cases. Eur J Med Genet (2005) 0.92
Protein profiling of oral brush biopsies: S100A8 and S100A9 can differentiate between normal, premalignant, and tumor cells. Proteomics Clin Appl (2007) 0.92
Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation (2002) 0.91
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol (2003) 0.91
The double hatchet flap as a potential alternative closure technique for scalp defects. J Dtsch Dermatol Ges (2015) 0.91
Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol (2007) 0.91
Molecular cytogenetic characterization of eight small supernumerary marker chromosomes originating from chromosomes 2, 4, 8, 18, and 21 in three patients. J Appl Genet (2007) 0.91
Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics (2003) 0.91
Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics (2006) 0.91
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol (2009) 0.91
Short German guidelines: basal cell carcinoma. J Dtsch Dermatol Ges (2008) 0.91
Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging (2012) 0.90
MALDI-imaging segmentation is a powerful tool for spatial functional proteomic analysis of human larynx carcinoma. J Cancer Res Clin Oncol (2012) 0.90
Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. Int J Oncol (2007) 0.90
Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. Cancer Res (2009) 0.90
Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms. J Invest Dermatol (2008) 0.89
Proteome analysis of maternal serum samples for trisomy 21 pregnancies using ProteinChip arrays and bioinformatics. J Histochem Cytochem (2005) 0.89
PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep (2006) 0.89
Interactions of TANGO and leukocyte integrin CD11c/CD18 regulate the migration of human monocytes. J Leukoc Biol (2007) 0.89
Mechanical stretch induces clustering of beta1-integrins and facilitates adhesion. Exp Dermatol (2006) 0.89
Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol (2007) 0.88
Long-term lowering of tumour interstitial fluid pressure reduces Ki-67 expression. J Biomech (2006) 0.87
Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol (2005) 0.87